On biomarkers, acquired resistance and immune escape, oh my!
Finding targets for combinatorial therapy to combat cancer resistance
Which combinations make rational sense and which might see action in the clinic?
Some truly novel approaches to tackling advanced cancers
A look atfive recent developments and what we can learn from them
When switching therapy areas things can get interesting in unexpected ways...
Interpreting some of the early trails reading out at ASCO24
Segueing between preclinical and clinical data
Where epigenetics and synthetic lethality converge
Our 7th AACR Preview takes stock of an emerging class of anti-cancer agents
In our fifth preview from the AACR annual meeting being held in San Diego next month, we noticed some…
It's time to start pointing the way for new directions in the Menin niche
Next generation CAR-T cells are coming to the clinic in 2024
Hats off to companies pursuing an emerging target in breast cancer
In our latest Preview from the American Society of Hematology, we’re using the dragon’s…
How a competitive landscape can change drastically over a short time
More gems from the TARGETS23 poster halls
What to watch out for in DDR, epigenetic therapies, and other hot topics
From epigenetics to SHP2, a look at various upcoming presentations this month
A look at some hot topics from the TARGETS/TRIPLE meeting in Boston
What we can learn from scientific talks at WCLC in order to improve clinical development
Finding the sweetspot in early stage cancer drug development
One of the challenging and frustrating aspects of oncology drug development is in knowing a target is…
How we can use AI to improve scientific writing and reports
A potentially novel approach for some advanced breast cancers
Tackling intractable cancers with a novel and creative approach to the problem
What do three phase 1 and one phase 2 trials tell us about future development?
Have you ever wondered why some anti-cancer agents do well and others poorly – even with similar…
Off the beaten track can bring danger and delight in the unknown in equal measure
Update on Developmental Therapeutics
Where we explain what to look for in 10 posters presented at AACR23
W2W4 on the TPD front
The ever evolving selective KRAS inhibitor & degrader space
A look at an emerging early stage oncology landscape
Continuing our evaluation and exploration of another batch of early stage anti-cancer compounds either…
A novel approach to targeting an intractable oncogene
Ten emerging development areas to watch out for in oncology during 2023
Some key subtleties and nuances to watch out for in the Menin niche
The importance of T cell exhaustion and exploring ways to avoid it
The beat goes on for synthetic lethal approaches
Are there opportunities for combining small molecule inhibitors with protein degraders?
6 abstracts to watch out for on how to overcome immune escape
Just because a pathway has been called undruggable doesn't always mean it will be so!
9 hidden Gems from the ASH21 poster hall and why you should pay attention to them
A look at new data in the Menin/MLLr inhibitor landscape in acute leukemias
What's hot in early preclinical development to watch out for?
Emerging areas in cool new science around targeted therapies
Highlights on translational research and clinical trials in AML and BCLA CAR T cell therapy
W2W4 in targeted therapies at ASH20 - some key early stage areas to focus on
A novel epigenetic target may have far-reaching outcomes for cancer patients
One particular presentation stood out from the others at AACR20 this year
Commentary on Day 1 of the AACR20 Virtual Meeting
Ten intriguing novel agents in early development to watch out for
A look at a wide array of targets, modalities, new agents and companies through the lens of targeted therapies
In the first part of the review on novel targets in hematologic malignancies, we covered five key areas…
Update on Kura Oncology's progress with tipifarnib and their emerging pipeline
Key findings and commentary on the third day of ESMO
A potential role for epigenetic therapies in straddling the divide between transcription factors and the immune system...
A look at a selection of promising Developmental Therapeutics abstracts from ASH17 - what's in store this year?
What's new about p53 mutants and MDM2 inhibitors?
A look st Syndax's entinostat and what happens when given in combination with pembrolizumab in melanoma and lung cancer
A fireside chat with a leading KOL involved in cancer research on resistance.
After exploring a mechanistic approach and a tumour type as part of our AACR annual meeting coverage, in…
Going beyond proteasome inhibitors and IMiDs in multiple myeloma - what novel targets are attractive?
What are the new targets and drug combinations that are emerging in triple negative breast cancer (TNBC)? find out more about the promising developments in this field.
